Harmony Biosciences (HRMY) Tops Q4 EPS by 28c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Harmony Biosciences (HRMY) Tops Q4 EPS by 28c

Harmony Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

February 28, 2022 7:30 AM EST

WAKIX® (pitolisant) Net Revenue Increased 62% Year-over-Year to $91.2 Million for Fourth Quarter 2021 and 91% to $305.4 Million for Full Year

Achieved First Full Year of Profitability and Net income was $22.7 Million for the Fourth Quarter 2021

Average Number of Patients on WAKIX Increased to ~3,800

On Track to Initiate the Phase 3 Clinical Trial in Patients with Idiopathic Hypersomnia First Half of This Year

 Year-End 2021 Cash and Cash Equivalents of Approximately $234 Million

Conference Call and Webcast to be Held Today at 8:30 a.m. ET 

... More